SABCS 2021 | ALTERNATE: neoadjuvant endocrine treatment in ER+/HER2- breast cancer

Cynthia X. Ma, MD, PhD, Washington University in St. Louis, St. Louis, MO, discusses the results of the ALTERNATE study (NCT01953588), an Alliance trial evaluating Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC). This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.